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Purpose. To report a comparative prospective long-term functional analysis after Riboﬂavin UV A corneal cross-linking (CXL) in
three diﬀerent age groups of patients aﬀected by progressive keratoconus (KC). Methods. Functional analysis comprised paediatric
patients (≤18 years) included 152 eyes (29.5%); intermediate group (19–26 years) 286 eyes (55.4%), and adults (≥27 years) 78
eyes (15.1%). CXLwas performed according to the Siena protocol by using the Vega CBM (Caporossi-Baiocchi-Mazzotta) X linker
(CSO, Florence, Italy) at Siena University by the same authors. Pre- and post-op examinations included UCVA, BSCVA, corneal
topography, and surface aberrometry (CSO Eye Top, Florence, Italy), at 48 months followup. Results. At 48 months followup
paediatrics, intermediate, and adult patients showed a mean gain in UCVA of +0.2, +0.14 and +0.12 Snellen lines. BSCVA gained
by a mean of +0.21, +0.2, and +0.1 Snellen lines. Kmax was reduced by a mean value of −0.9D, −0.6D, and −0.5D, respectively.
Comavaluesimprovedbyameanof −0.45µm, −0.91µm,and −0.19µm,respectively.Treatmentensuredalong-termkeratoconus
stabilizationinover90%oftreatedpatients.Conclusion.Accordingtoourlong-termcomparativeresults,epithelium-oﬀRiboﬂavin
UV A cross-linking should be the ﬁrst choice therapy of progressive KC, particularly in paediatric age and patients under 26 years.
1.Introduction
Paediatric age at the time of diagnosis represents a neg-
ative prognostic factor for keratoconus progression, with
increased probability of corneal transplant [1].
Particularly younger patients represent a population at
highriskformorerapidprogressionofthedisease[1,2].The
long-term results reported in literature [3–5]h a v ed e m o n -
strated the ability of cross-linking to slow the progression
of keratoconus by a photo-polymerization reaction of stro-
mal collagen ﬁbres. Cross-linking photodynamic reaction
is induced by the combined action of a photosensitizing
substance (Riboﬂavina o vitamin B2) and ultraviolet (UV) A
light, allowing a corneal stiﬀening by increasing the number
of intraﬁbrillar, interﬁbrillar covalent bonds, and corneal
collagen resistance against enzymatic degradation [6–8]. The
long-termeﬀectsofthetechniquearerelatedalsotoaprocess
ofcollagenneosynthesiswithadiﬀerentstructureandhigher
molecularweight [9–12] whichconfersto the cornealstroma
an increased resistance and lamellar compaction responsible
of the variable functional modiﬁcations recorded after the
treatment [11–14].
According to international results [3–5], cross-linking
should be the primary choice in young patient with progres-
sive keratoconus.
2. Purpose
To report a comparative prospective long-term functional
analysis after cross-linking in three diﬀerent age groups
(≤18 years, between 19–26 years, and ≥27 years) of patients
aﬀected by progressive keratoconus.
3. Methods
Since 2004 to date more than 610 patients were treated by
combined Riboﬂavin UV A corneal collagen cross-linking.2 Journal of Ophthalmology
Present prospective nonrandomized open study comprised
516 eyes of 413 patients aged between 10 and 40 years,
aﬀected by progressive keratoconus.
The comparative functional analysis comprised the fol-
lowing:
(1) paediatric group (18 years and under) included 152
eyes of 105 patients (29.5%),
(2) intermediate group (19–26 years) included 286 eyes
of 243 patients (55.4%),
(3) Adult group (≥27 years) included 78 eyes of 65
patients (15.1%).
3.1. Inclusion Criteria. All patients included in the treatment
protocol were aﬀected by progressive keratoconus with a
documented clinical and instrumental worsening at least
in the last three months of observation. The parameters
we considered to establish keratoconus progression were
worsening of UCVA/BSCVA > 0.50 Snellen lines, increase
of SPH/CYL > 0.50D, increase of topographic symmetry
index SAI/SI > 0.50D, increase of maximum K reading >
0.50D, reduction of the thinnest point at optical pachom-
etry ≥10µm, clear cornea at biomicroscopic examination,
absence of reticular dark striae at confocal laser microscopy
invivo.Patientswithoutpossibilityofopticalcorrectionwere
also included. We considered “signiﬁcant” for the inclusion
in the study the variation of at least 3 of the parameters
listed above (one clinical plus two instrumental). Statistical
analysis was conducted by the Mann-Whitney U test for
nonparametric data (UCVA and BSCVA) and by the paired
t test for parametric data (maximum curvature power,
symmetry indices and coma values).
3.2. Surgical Technique. The surgical procedure of corneal
cross-linking with Riboﬂavina UVA was performed in all
patients according to the Siena protocol [3] using the
Vega CBM (Caporossi-Baiocchi-Mazzotta) X linker (CSO,
Florence, Italy) developed in Italy at the Department of
Ophthalmology of Siena University by the same Authors,
under intellectual property of Siena University, Italy. The
treatment was conducted under topical anaesthesia (4%
lidocaine drops). After applying the eyelid speculum, a 9mm
diameter marker was used to mark the corneal epithelium in
a central circle, then epithelium was removed with a blunt
metal spatula. After epithelial scraping, a disposable solution
of Riboﬂavin 0.1% and Dextrane 20% (Ricrolin Sooft, Mon-
tegiorgio, Italy) was instilled for 10 minutes [15]o fc o r n e a l
soaking before starting UV A irradiation. The Riboﬂavin
and Dextrane solution was administered every 2.5 minutes
for a total of 30 minutes of UVA exposure (3mW/cm2).
Treated eyes were dressed with a therapeutic soft contact lens
bandagefor4daysandmedicatedwithantibiotics(Oﬂoxacin
drops 4times/day), nonsteroidal anti-inﬂammatory drugs
(Diclofenac drops 4times/day) and lachrymal substitutes,
until contact lens removal. After therapeutic corneal lens
removal, ﬂuorometholone 0.2% drops (3times/day) and
lacrimal substitutes were administered for 6 to 8 weeks.
3.3. Followup and Assessment Criteria. (1) 152 eyes of 105
patients ≤18 years (91 eyes with followup of 12 months, 74
eyes at 24 months, 25 eyes at 36 months, 7 at 48 months).
(2) 286 eyes of 243 patients between 19 and 26 years (108
eyes with followup 12 months, 83 eyes at 24 months, 56 eyes
at 36 months, 11 at 48 months).
( 3 )7 8e y e so f6 5p a t i e n t s≥27 (35 eyes with followup 12
months, 25 eyes at 24 months, 12 eyes at 36 months, 8 at 48
months).
Pre- and postoperative examination included uncor-
rected visual acuity (UCVA), best spectacle corrected visual
acuity (BSCVA), corneal topography and surface aberrom-
etry (CSO Eye Top, Florence, Italy), optical pachometry
(Visante OCT, Zeiss Meditech, Jena, Germany), and in vivo
confocal microscopy (HRT II, Heidelberg, Rostock Cornea
Module, Germany).
4. Results
According to epidemiology ﬁndings [16], we found a
male/female ratio in the whole sample of 4:1; a male/female
ratio in paediatric group of 6:1, and a male/female ratio of
3:1 in patients between 19 and 40 years old. These results,
even if in a small group, diﬀer from epidemiological data
reported in the literature [16] were a male/female rate of
2:1 is reported. There was no statistical diﬀerence in the
incidence of keratoconus between right and left eye in the
whole population of 516 eyes and age-related groups.
4.1. Functional Results. Comparative UCVA in patients ≤18
years showed a mean gain of +0.14 (P = 0.0037), +0.17 (P =
0.0043), +0.16 (P = 0.0051) and +0.2 (P = 0.006) Snellen
lines at 12, 24, 36, and 48 months of followup, respectively.
Patients between 19 and 26 years showed a mean gain of
+0.13(P = 0.0034),+0.16(P = 0.0041),+0.12(P = 0.0032),
and +0.14 (P = 0.0073) Snellen lines at 12, 24, 36, and 48
months of followup, respectively.
Patients ≥27 years showed a mean gain of +0.08 (P =
0.0036), +0.09 (P = 0.005), +0.12 (P = 0.0047) and +0.12
(P = 0.0071) Snellen lines at 12, 24, 36, and 48 months of
followup, respectively, (Figure 1).
Comparative BSCVA in patients ≤18 years showed a
mean gain of +0.15 (P = 0.0056), +0.19 (P = 0.0031), +0.18
(P = 0.0059) and +0.21 (P = 0.0079) Snellen lines at 12, 24,
36, and 48 months of followup, respectively.
Patients between 19 and 26 years showed a mean gain of
+0.10(P = 0.0052),+0.12(P = 0.0045),+0.13(P = 0.0056),
and +0.2 (P = 0.0075) Snellen lines at 12, 24, 36, and 48
months of followup, respectively.
Patients ≥27 years showed a mean gain of +0.07 (P =
0.0054), +0.06 (P = 0.0067), +0.08 (P = 0.0069), and +0.10
(P = 0.0075) Snellen lines at 12, 24, 36, and 48 months of
followup, respectively, (Figure 2).
4.2. Topography Results. Kmax in paediatric group varied by a
mean of −0.7D (P = 0.006), −0.8D (P = 0.0045), −1.1D
(P = 0.051), and −0.9D (P = 0.071); in the intermediate
group (patients between 19 and 26 years) varied by a mean
of −0.6D (P = 0.0053), −0.5D (P = 0.0051), −0.3D (P =
0.0045), and −0.6D (P = 0.0091); in adult group (patientsJournal of Ophthalmology 3
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Figure 1: Graph showing visual performance during followup.
After cross-linking, uncorrected visual acuity (UCVA) in patients
≤18 years showed a mean gain of +0.14, +0.17, +0.16, and +0.2
Snellen lines at 12, 24, 36, and 48 months of follow-up, respectively;
in patients between 19 and 26 years showed a mean gain of +0.13,
+0.16, +0.12, and +0.14 Snellen lines at 12, 24, 36, and 48 months
of followup, respectively; and in patients ≥27 years showed a mean
gain of +0.08, +0.09, +0.12, and +0.12 Snellen lines at 12, 24, 36,
and 48 months followup, respectively.
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Figure 2: Graph showing visual performance during followup.
After cross-linking, best spectacle-corrected visual acuity (BSCVA)
in patients ≤18 years showed a mean gain of +0.15, +0.19, +0.18
and +0.21 Snellen lines at 12, 24, 36, and 48 months of followup,
respectively; in patients between 19 and 26 years showed a mean
gain of +0.10, + 0.12, +0.13, and +0.2 Snellen lines at 12, 24, 36,
and 48 months followup, respectively; in patients ≥27 years showed
a mean gain of +0.07, +0.06, +0.08, and +0.10 Snellen lines at 12,
24, 36 and 48 months of followup, respectively.
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Figure 3: The graph showing computerized corneal topography
results. The comparative topographic analysis showed a Kmax
variation in paediatric group by a mean of −0.7D, −0.8D, −1.1D,
and −0.9D; in the intermediate group (patients between 19 and
26 years) varied by a mean of −0.6D, −0.5D, −0.3D, and −0.6D;
in adult group (patients ≥27 years) varied by a mean of −0.4D,
−0.6D, −0.5D, and −0.5D, at 12, 24, 36, and 48 months of
followup, respectively, for each group.
≥27 years) varied by a mean of −0.4D (P = 0.0065),
−0.6D (P = 0.0074), −0.5D (P = 0.0095), and −0.5D
(P = 0.0091), at 12, 24, 36, and 48 months of follow-up,
respectively for each group (Figure 3).
Surface asymmetry index (SAIm) in paediatric patients
improvedbyameanvalueof, −0.42D(P = 0.0054), −0.18D
(P = 0.0066), −0.24D (P = 0.091), and − 0.10D (P =
0.096); in the intermediate group improved by a mean of,
−1.05D (P = 0.0032), −1.14D (P = 0.0021), −0.84D
(P = 0.0036), and −0.65D (P = 0.076); in adult group
improved by a mean of, −0.52D (P = 0.0067), −1.0D (P =
0.0077), −0.17D (P = 0.0081), and − 1.11D (P = 0.0094),
(Figure 4).
Topographic superior-inferior symmetry index (SIm)
in paediatric patients varied by a mean of, +0.3D (P =
0.0098),+0.6D(P = 0.011),+0.2D(P = 0.017),and+1.5 D
(P = 0.021);intheintermediategroupchangedbyameanof,
−0.42D (P = 0.0086), −0.55D (P = 0.0079), +0.90D (P =
0.091), and +0.40D (P = 0.099); in adult patients varied by
am e a no f ,−0.26D (P = 0.0059), −0.21D (P = 0.0048),
+1.17D (P = 0.012), and −0.21D (P = 0.0011) at 12, 24, 36,
and 48 months of followup, respectively, (Figure 5).
4.3. Aberrometry Results. Coma values in paediatric patients
improved by a mean of −0.47µm( P = 0.0034), −0.52µm
(P = 0.0025), −0.47µm( P = 0.0022), and −0.45µm( P =
0.0054); in the intermediate group coma values decreased by4 Journal of Ophthalmology
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Figure 4: Graph showing anterior corneal surface aberrometry
after corneal cross-linking (SAI m) in paediatric patients improved
by a mean of, −0.42D, −0.18D, −0.24D, and −0.10D; in the
intermediate group improved by a mean of, −1.05D, −1.14D,
−0.84D, and −0.65D; in adult group improved by a mean of,
−0.52D, −1.0D, −0.17D, and −1.11D.
PREOP 3◦M6 ◦M1 2 ◦M2 4 ◦M3 6 ◦M4 8 ◦M
4
5
6
8
9
10
11
12
13
14
7
SI
D
10.12 10.27 10.13 9.86
9.91 11.29
9.91
9.68 9.56 9.18 9.26
9.13
10.57
10.09
7.55
8.84
7.66 7.97 7.75 7.67 7.32
SI < 18Y
SI 19–26Y
SI > 18Y
Figure 5:Graphshowingtopographicanalysisofcornealsymmetry
using the superior-inferior index (SI). After cross-linking SI
improved in paediatric patients by a mean of +0.3D, +0.6D, +0.2D
and +1.5D; in the intermediate group changed by a mean of:
−0.42D, −0.55D, +0.90D, +0.40D; in adult patients varied by a
mean of: −0.26D, −0.21D, +1.17D, −0.21D at 12, 24, 36 and 48
months of follow-up respectively.
am e a no f−0.89µm( P = 0.0034), −0.96µm( P = 0.0065),
−0.93µm( P = 0.0074), and −0.91µm( P = 0.0081); in old
patients we recorded a mean postoperative value of −0.2µm
(P = 0.0056), −0.18µm( P = 0.0045), −0.21µm( P =
0.0034), and −0.19µm( P = 0.0067) at 12, 24, 36 and 48
months of followup respectively, (Figure 6).
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Figure 6: Graph showing the COMA analysis and the improving
value in paediatric patients by a mean of −0.47µm, −0.52µm,
−0.47µm, and −0.45µm; in the intermediate group coma values
decreased by a mean of −0.89µm, −0.96µm, −0.93µm, and
−0.91µm; in old patients we recorded a mean postoperative value
of −0.2µm, −0.18µm, −0.21µm, and −0.19 µm at 12, 24, 36, and
48 months of followup, respectively.
5. Discussion
According to the literature in [1] and our previous reports
[3], keratoconus progression is more frequent and faster in
younger patients under 18 years old at the time of diagnoses,
with higher probability to undergo a corneal transplantation
[1, 3]. Therefore paediatric patients represent the goal of
photo-induced Riboﬂavin UV A corneal collagen cross-
linking [3].
The Italian pilot study “Siena CXL Paediatrics”, con-
ducted on a large cohort of patients with a long-term
follow up, demonstrated that there was a signiﬁcant and fast
functional improvement in younger patients after Riboﬂavin
UV A corneal cross-linking.
As we recently published, it is however impossible
to exactly predict the distribution of cross-links and the
geometric redistribution of newly formed collagen [12, 14].
Long-term comparative analysis showed that functional
results after Riboﬂavin UV A corneal collagen cross-linking
among paediatric patients were slightly better, but without
statisticallysigniﬁcantdiﬀerenceswiththeresultsrecordedin
the intermediate group patients. On the other hand, patients
over 27 years showed a positive but poorer functional
response compared with other age groups.
The mean Kmax variation and topographic surface
asymmetry index results were statistically signiﬁcant in
the paediatric sample, particularly in the postoperative 24
months. After the 24th month, until the 48th month, the
meandataresultswerestatisticallynotsigniﬁcant,reasonably
due to reduced number of patients in the longitudinal
analysis.Journal of Ophthalmology 5
The comparative aberrometric data of coma values
showed a signiﬁcant improvement in all analyzed groups,
justifying the rapid improvement of visual acuity in all
treated patients. In the paediatric group of our cohort, there
was a minority of patients (about 5%) that, despite the
treatment, showed a worsening trend or at least an instability
of keratoconus. In our opinion, this concept should be
remarked because the disease in this age group is more
aggressive and the possibility of progression higher than
in the others age groups. The instability of certain cases
should be explained by the diﬀerent genetic patterns of
keratoconus [17–19]withrelative biochemicalmodiﬁcations
[20] potentially occurring in corneal stroma associated with
negative inﬂuences of some environmental factors (allergy,
atopy) [21–24].
Every time we decide to treat a paediatric patient under
18 years aﬀected by progressive keratoconus, parents and
patient himself should be well informed about the possibility
that the treatment in a minority of cases could not warrant
a total and long-lasting stabilization of the disease, with the
possibility to repeat the cross-linking or to undergo alter-
native treatments. The “Siena CXL Paediatrics” pilot study
demonstrated the eﬀective ability of corneal cross-linking to
retard keratoconus progression in all age groups with better
functional response in patients under 26 years. Treatment
ensured a long-term keratoconus stabilization in over 90%
of treated cases. The lower functional response observed in
patientsover27yearsmaybeexplainedbyareducedcollagen
“plasticity” in the adult age, as well demonstrated in the
literature [25, 26]. Cross-linking treatment may result in less
eﬀectiveness with increased failure and complication rate
particularly in adult patients over 35 years, as reported in
the literature [21]. According to our long-term comparative
age-related analysis and results, the standard Riboﬂavin UV
A cross-linking with epithelium removal should be the ﬁrst
choice therapy of progressive keratoconus in paediatric and
under-26-year old patients with corneal thickness at least of
400µm in the thinnest point.
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